AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34995128
Drug: Early locoregional
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early locoregional therapy
Trial: 34995204
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, 4 sessions over 5 weeks
Trial: 34995818
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid (CS) eye drops monitored with Kali Drop device
Trial: 34996114
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) treatment for 6 weeks in addition to mood stabilizer
Trial: 34996784
Drug: Antithrombotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatments
Trial: 34996920
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAA)
Trial: 34997267
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (55 mg elemental iron from ferrous sulphate, once daily for 3 months)
Trial: 34997701
Drug: Odronextamab (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (320 mg weekly)
Trial: 34997701
Drug: Odronextamab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (0.5 mg dose)
Trial: 34997701
Drug: Odronextamab (1-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (1-10 mg/L) in Raji xenograft tumor mouse model
Trial: 34997825
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 5 g
Trial: 34998033
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake (DPI)
Trial: 34998377
Drug: Multiplex PCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiplex PCR test plus autoimmune antibody testing
Trial: 34998377
Drug: mNGS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mNGS plus autoimmune antibody testing
Trial: 34998471
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg once every 2 weeks plus apatinib 250 mg once daily for a 28-day cycle
Trial: 39745702
Drug: Recombinant quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant quadrivalent influenza vaccine (RIV4)
Trial: 34998605
Drug: Standard-dose quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4)
Trial: 34998740
Drug: Optimal combination
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal combination of AI-ECG outputs from pulmonary and handheld positions
Trial: 34999659
Drug: Depleting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depleting therapy in the past year
Trial: 35000420
Drug: preCARDIA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preCARDIA therapy for 12 or 24 hours
Trial: 35001051
Drug: Nonanimal stabilized
RxNorm normalized name: nonanal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonanimal stabilized hyaluronic acid/dextranomer treatment
Trial: 35002791
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine treatment for 12 weeks
Trial: 35003094
Drug: Anti-IL1RAP antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL1RAP antibody (nadunolimab, CAN04)
Trial: 35003503
Drug: Self-Administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Administration of Auricular Acupuncture
Trial: 35004718
Drug: Prescription intervention;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription intervention; details not available
Trial: 35005393
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral methadone
Trial: 35005411
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy-based bibliotherapy intervention
Trial: 35005777
Drug: Antifungal treatment
RxNorm normalized name: TOLNAFTATE 10 mg in 1 mL TOPICAL LIQUID [Liquid Antifungal Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifungal treatment (oral or topical)
Trial: 35005777
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events (treatment and control groups)
Trial: 35007745
Drug: Hazelnut oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hazelnut oral immunotherapy (H-OIT)
Trial: 35012889
Drug: VPM1002BC (intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPM1002BC (intravesical treatment, 6 weekly instillations followed by maintenance for 1 year)
Trial: 35012889
Drug: VPM1002BC (intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPM1002BC (intravesical treatment)
Trial: 35013456
Drug: ssCART-19 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ssCART-19 treatment in low tumor burden group
Trial: 35013456
Drug: ssCART-19 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ssCART-19 treatment in high tumor burden group
Trial: 35013456
Drug: ssCART-19 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ssCART-19 treatment
Trial: 35014900
Drug: Reduced-dose deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose deep learning image reconstruction (DLIR)
Trial: 35014900
Drug: Standard-dose filtered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose filtered back projection (FBP)
Trial: 35014900
Drug: Both reduced-dose
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both reduced-dose DLIR and standard-dose FBP
Trial: 35015819
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks for up to 16 cycles) and Rituximab (375 mg/m2 IV weekly for 4 weeks in cycle 1 only)
Trial: 35015828
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant (LA)
Trial: 35015879
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g FOS
Trial: 35015879
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g acacia gum
Trial: 35015879
Drug: 6.1 g
RxNorm normalized name: CHLOROXYLENOL 6.1 g in 1 L TOPICAL SOAP [Antibacterial Hand]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.1 g lactose and 1.5 g sucrose (control)
Trial: 35015980
Drug: Daily exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exposure to mild intermittent hypoxia
Trial: 35016146
Drug: Oral D/L-Na-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D/L-Na-lactate
Trial: 35016146
Drug: Intravenous iso-lactemic
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iso-lactemic D/L-Na-lactate
Trial: 35017154
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily)
Trial: 35017197
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in mice
Trial: 35018097
Drug: mirtazapine+SNRIs+physical therapies
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mirtazapine+SNRIs+physical therapies
Trial: 35018342
Drug: Vagus Nerve
RxNorm normalized name: SUS SCROFA VAGUS NERVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagus Nerve Stimulation Therapy (VNS Therapy)
Trial: 35018370
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus fitness tracker (TAU+)
Trial: 35018553
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg once daily (QD)
Trial: 35018553
Drug: Lorlatinib 100
RxNorm normalized name: lorlatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib 100 mg QD
Trial: 35018553
Drug: Lorlatinib 75
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lorlatinib 75 mg QD
Trial: 35018878
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulant within four days of stroke onset
Trial: 35018878
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of direct oral anticoagulant, 7 to 14 days from onset
Trial: 35018878
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of direct oral anticoagulant
Trial: 35018878
Drug: Delayed initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delayed initiation of direct oral anticoagulant
Trial: 35020185
Drug: Opioid taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid taper
Trial: 35021863
Drug: Hepatic irradiation
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic irradiation with Yttrium-90 microspheres followed by immunotherapy with Ipilimumab and Nivolumab
Trial: 35022035
Drug: Monocyte-Derived Dendritic-cell
RxNorm normalized name: MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC FACTOR
DrugBank: Human Interleukin 8 (DB16456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocyte-Derived Dendritic-cell Therapy (MDDCT)
Trial: 35022321
Drug: ONC201 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (625 mg orally weekly) in arm A (PC-PG)
Trial: 35022321
Drug: ONC201 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (625 mg orally weekly) in arm B (other neuroendocrine tumors)
Trial: 35022321
Drug: ONC201 (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (625 mg orally on 2 consecutive days each week) in arm C (PC-PG)
Trial: 35022322
Drug: oHSV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oHSV treatment with NOTCH blockade
Trial: 35022322
Drug: oHSV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oHSV treatment
Trial: 35022711
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of SARS-CoV-2 antibodies (IgA, IgM, IgG, and/or total Ig)
Trial: 35022711
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of SARS-CoV-2 antibodies
Trial: 35022790
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with ACE inhibitors (ACEis)
Trial: 35025062
Drug: Deucravacitinib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib (3 mg twice daily, 6 mg twice daily, 12 mg once daily)
Trial: 35025555
Drug: Smartphone-delivered attentional
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-delivered attentional bias modification (ABM) training for 13 days as an adjunct to smoking cessation treatment
Trial: 35027038
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with glucarpidase
Trial: 35027038
Drug: MTX-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX-based therapy
Trial: 35027656
Drug: cfDNA positivity
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cfDNA positivity (≥10% tumor fraction by LPWGS) after two cycles of treatment
Trial: 35027656
Drug: cfDNA negativity
RxNorm normalized name: CFDN
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cfDNA negativity (tumor-negative) after two cycles of treatment
Trial: 35027752
Drug: Olpasiran (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran (9 mg or higher)
Trial: 35027752
Drug: Olpasiran (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran (single doses)
Trial: 35027752
Drug: Olpasiran (dose-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olpasiran (dose-escalation trial)
Trial: 35028673
Drug: Antibiotics and
RxNorm normalized name: Antibiotics and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics and caffeine among preterm infants
Trial: 35028673
Drug: General drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General drug utilisation patterns
Trial: 35028673
Drug: Non-evidence-based drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-evidence-based drugs
Trial: 35028673
Drug: Rational drug
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational drug use
Trial: 35030234
Drug: 200,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200,000 IU Vitamin A Supplementation (VAS) administered before and 4 weeks after measurement
Trial: 35031227
Drug: Obinutuzumab 1000
RxNorm normalized name: obinutuzumab 1000 MG in 40 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab 1000 mg IV in cycle 1, followed by obinutuzumab plus atezolizumab 1200 mg IV for cycles 2-8, and atezolizumab only from cycle 9.
Trial: 35031227
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus atezolizumab 1200 mg IV
Trial: 35031227
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg IV every 3 weeks (RP2D)
Trial: 35031547
Drug: NT-I7 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-I7 (10 mg/kg on the final day of RT)
Trial: 35033008
Drug: Neoadjuvant chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiation therapy (nCRT) using MRI guided radiotherapy (MRgRT) with 55 Gy in 25 fractions on Gross Tumor Volume (GTV) and 45 Gy in 25 fractions on drainage nodes, along with continuous chemotherapy with 5-fluoracil (5-FU) or oral capecitabine.
Trial: 35033008
Drug: MRI guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI guided radiotherapy (MRgRT) with dose escalation based on early tumour regression index (ERI).
Trial: 35033092
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg once daily (qd) as part of triple combined antiretroviral therapy (cART)
Trial: 35033092
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg qd
Trial: 35033182
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10
Trial: 35033182
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg administered once daily intravenously for 10 days
Trial: 35033999
Drug: Nonbiologic disease-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbiologic disease-modifying antirheumatic drugs (nbDMARDs)
Trial: 35034046
Drug: Budigalimab 250
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab 250 mg Q2W or 500 mg Q4W
Trial: 35034080
Drug: Hypertension treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension treatment at registration
Trial: 35034080
Drug: Hypertension treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension treatment at the end of the baseline visit
Trial: 35034116
Drug: Weight Loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight Loss (WL) + higher NfL (>94.55 pg/mL, highest quartile)
Trial: 35034116
Drug: Weight Loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight Loss (WL) + higher progranulin (>38.4 ng/mL, 3 higher quartiles)
Trial: 35035223
Drug: Meropenem treatment
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem treatment
Trial: 35035233
Drug: TAP-DEX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP-DEX group (bupivacaine + 1 µg/kg dexmedetomidine)
Trial: 35036077
Drug: Combined radiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiotherapy and anti-PD-1 antibody camrelizumab
Trial: 35036831
Drug: Ketamine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine as an adjunctive therapy
Trial: 35036831
Drug: Ketamine as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine as an adjunctive therapy for major depression
Trial: 35037887
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care involving keeping written records of glucose values and contacting the diabetes team daily by telephone.
Trial: 35037893
Drug: Optimized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized medical treatment
Trial: 35038983
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg PRN
Trial: 35039142
Drug: Ginger (Zingiberofficinale)
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (Zingiberofficinale) add-on therapy, 399 mg three times per day for 6 weeks
Trial: 35039242
Drug: Nocturnal urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal urine production >90 ml/h (NUP90)
Trial: 35039291
Drug: Camu Camu
RxNorm normalized name: CAMUSTINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camu Camu (CC) supplementation
Trial: 35039952
Drug: Sulindac 150
RxNorm normalized name: sulindac 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac 150 mg twice daily
Trial: 35040156
Drug: Adalimumab (s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (s.c. doses according to package insert)
Trial: 35041493
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg once daily) plus binimetinib (30 mg twice daily)
Trial: 35041751
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (duration: 12 months)
Trial: 35042068
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg every four weeks
Trial: 35042460
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy treatment
Trial: 35042555
Drug: Anti-CCP+ individuals
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CCP+ individuals with high antibody levels
Trial: 35042560
Drug: TXA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 500 mg two times daily for 28 days
Trial: 35042560
Drug: Placebo two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two times daily for 28 days
Trial: 35042560
Drug: TXA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA 500 mg
Trial: 35043682
Drug: Subsequent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent treatment for mCRC patients
Trial: 35043682
Drug: Patient-reported outcomes
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported outcomes using a modified version of the ACCEPTance by the Patients of their Treatment
Trial: 35043686
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pembrolizumab and laser interstitial thermal therapy
Trial: 35043976
Drug: VB124 (MCT4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VB124 (MCT4 inhibitor)